MedTrace Logo

Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

NCT00790699 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2020-10-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether injecting Symlin and insulin through a multiple injection port is safe and effective. This will be measured by HbA1c values taken at the beginning of the study and at the final visit.

The secondary objective of the study is to measure patient satisfaction toward using the multiple injection port.

Conditions

Interventions

DEVICE

I-PORT

The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.

OTHER

standard injections

The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.

Sponsors & Collaborators

  • Amylin Pharmaceuticals, LLC.

    collaborator INDUSTRY

  • Texas Diabetes & Endocrinology, P.A.

    lead OTHER

Principal Investigators

  • Thomas C. Blevins, MD · Texas Diabetes & Endocrinology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00790699 on ClinicalTrials.gov